These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 34026332)

  • 1. Activity-regulated cytoskeleton-associated protein/activity-regulated gene 3.1 (Arc/Arg3.1) enhances dendritic cell vaccination in experimental melanoma.
    Zhang XW; Huck K; Jähne K; Cichon F; Sonner JK; Ufer F; Bauer S; Woo MS; Green E; Lu K; Kilian M; Friese MA; Platten M; Sahm K
    Oncoimmunology; 2021 May; 10(1):1920739. PubMed ID: 34026332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
    Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
    Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
    Wang J; Saffold S; Cao X; Krauss J; Chen W
    J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Local secretion of IL-12 augments the therapeutic impact of dendritic cell-tumor cell fusion vaccination.
    Tan C; Dannull J; Nair SK; Ding E; Tyler DS; Pruitt SK; Lee WT
    J Surg Res; 2013 Dec; 185(2):904-11. PubMed ID: 23891424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
    Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
    J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arc/Arg3.1 governs inflammatory dendritic cell migration from the skin and thereby controls T cell activation.
    Ufer F; Vargas P; Engler JB; Tintelnot J; Schattling B; Winkler H; Bauer S; Kursawe N; Willing A; Keminer O; Ohana O; Salinas-Riester G; Pless O; Kuhl D; Friese MA
    Sci Immunol; 2016 Sep; 1(3):eaaf8665. PubMed ID: 28783680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor immune response of dendritic cells (DCs) expressing tumor-associated antigens derived from induced pluripotent stem cells: in comparison to bone marrow-derived DCs.
    Iwamoto H; Ojima T; Hayata K; Katsuda M; Miyazawa M; Iida T; Nakamura M; Nakamori M; Iwahashi M; Yamaue H
    Int J Cancer; 2014 Jan; 134(2):332-41. PubMed ID: 23824921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
    Liu Y; Huang H; Chen Z; Zong L; Xiang J
    J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Inhibiting effect of IL-10 in tumor microenvironment on anti-tumor activity of SOCS1-silenced DC vaccine].
    Wang Z; You H; Song S
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Apr; 29(4):379-83. PubMed ID: 23643168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity.
    Prins RM; Craft N; Bruhn KW; Khan-Farooqi H; Koya RC; Stripecke R; Miller JF; Liau LM
    J Immunol; 2006 Jan; 176(1):157-64. PubMed ID: 16365406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arc/Arg3.1 defines dendritic cells and Langerhans cells with superior migratory ability independent of phenotype and ontogeny in mice.
    Tintelnot J; Ufer F; Engler JB; Winkler H; Lücke K; Mittrücker HW; Friese MA
    Eur J Immunol; 2019 May; 49(5):724-736. PubMed ID: 30786014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
    Liu Y; Saxena A; Zheng C; Carlsen S; Xiang J
    J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A short hairpin RNA-based adjuvant targeting NF-κB repressor IκBα promotes migration of dermal dendritic cells to draining lymph nodes and antitumor CTL responses induced by DNA vaccination.
    Gálvez-Cancino F; Roco J; Rojas-Colonelli N; Flores C; Murgas P; Cruz-Gómez S; Oyarce C; Varas-Godoy M; Sauma D; Lladser A
    Vaccine; 2017 Jul; 35(33):4148-4154. PubMed ID: 28666759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloid-derived Suppressor Cells Elimination by 5-Fluorouracil Increased Dendritic Cell-based Vaccine Function and Improved Immunity in Tumor Mice.
    Khosravianfar N; Hadjati J; Namdar A; Boghozian R; Hafezi M; Ashourpour M; Kheshtchin N; Banitalebi M; Mirzaei R; Razavi SA
    Iran J Allergy Asthma Immunol; 2018 Feb; 17(1):47-55. PubMed ID: 29512369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour-derived IL-10 within tumour microenvironment represses the antitumour immunity of Socs1-silenced and sustained antigen expressing DCs.
    Song S; Wang Y; Wang J; Lian W; Liu S; Zhang Z; Liu F; Wei L
    Eur J Cancer; 2012 Sep; 48(14):2252-9. PubMed ID: 22230748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer Stem Cell Vaccination With PD-L1 and CTLA-4 Blockades Enhances the Eradication of Melanoma Stem Cells in a Mouse Tumor Model.
    Zheng F; Dang J; Zhang H; Xu F; Ba D; Zhang B; Cheng F; Chang AE; Wicha MS; Li Q
    J Immunother; 2018 Oct; 41(8):361-368. PubMed ID: 30063587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activated natural killer cell-mediated immunity is required for the inhibition of tumor metastasis by dendritic cell vaccination.
    Kim A; Noh YW; Kim KD; Jang YS; Choe YK; Lim JS
    Exp Mol Med; 2004 Oct; 36(5):428-43. PubMed ID: 15557815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100.
    Xia DJ; Zhang WP; Zheng S; Wang J; Pan JP; Wang Q; Zhang LH; Hamada H; Cao X
    Gene Ther; 2002 May; 9(9):592-601. PubMed ID: 11973635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma.
    Bellone M; Cantarella D; Castiglioni P; Crosti MC; Ronchetti A; Moro M; Garancini MP; Casorati G; Dellabona P
    J Immunol; 2000 Sep; 165(5):2651-6. PubMed ID: 10946294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.